La Jolla Pharmaceutical won FDA approval Thursday for Giapreza, a drug that treats dangerously low blood pressure in adults with septic or other distributive shock.
Here are three things to know.
1. Giapreza is an injection that increases blood pressure in adults experiencing any form of distributive shock, a critical condition in which blood pressure drops so low that vital organs can't receive enough blood flow to function properly.
2. The FDA warns that Giapreza can cause blood clots, so a prophylactic treatment should be used.
3. La Jolla Pharmaceutical plans to make the drug available to U.S. patients in March 2018, according to Reuters.